For the quarter ending 2025-09-30, ZURA had -$15,473K decrease in cash & cash equivalents over the period. -$15,476K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,040 | -33,435 |
| Share-based compensation expense | 2,379 | 7,376 |
| Depreciation and amortization | 14 | 20 |
| Foreign exchange transaction loss (gain) | -6 | -67 |
| Prepaid expenses and other current assets | 780 | 249 |
| Other assets | 814 | - |
| Accounts payable and accrued expenses | 1,791 | -872 |
| Net cash used in operating activities | -15,444 | -27,093 |
| Purchase of property and equipment | 32 | 64 |
| Net cash used in investing activities | -32 | -64 |
| Proceeds from issuance of class a ordinary shares in connection with a sale under the atm, net of 0.2 million of commissions-At Market Offering | 0 | 5,093 |
| Proceeds from exercise of share options | 0 | 90 |
| Proceeds from exercise of pre-funded warrants | 3 | - |
| Payment of employee withholding taxes for restricted share units withheld | 0 | 34 |
| Net cash provided by financing activities | 3 | 5,149 |
| Net (decrease) increase in cash and cash equivalents | -15,473 | -22,008 |
| Cash and cash equivalents at beginning of period | 176,498 | - |
| Cash and cash equivalents at end of period | 139,017 | - |
Zura Bio Ltd (ZURA)
Zura Bio Ltd (ZURA)